RecruitingNCT06623487

The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer

The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial

Sponsor

Ruijin Hospital

Enrollment

30 participants

Start Date

Jul 19, 2024

Study Type

OBSERVATIONAL

Conditions

Carcinoma, Non-Small Cell Lung PET/CT Neoadjuvant Immunotherapy

Summary

Neoadjuvant immunotherapy can significantly improve the pathological complete response (pCR) and major pathological response (MPR) rates in resectable stage III non-small cell lung cancer (NSCLC), and extend the event-free survival (EFS). However, the current means for evaluating its efficacy are limited. This study aims to utilize the convenient and non-invasive 68Ga-grazytracer PET imaging to detect the aggregation of CD8+ T cells in target lesions after neoadjuvant immunotherapy for stage III NSCLC, and to assess its value in efficacy monitoring, providing valuable information for clinical treatment decisions.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether a special PET scan using a tracer called 68Ga-grazytracer can better predict and monitor how well immunotherapy is working in people with stage III non-small cell lung cancer (NSCLC). The goal is to see if this imaging tool can identify who will respond well to treatment before surgery. **You may be eligible if...** - You have stage III NSCLC that requires pre-surgical immunotherapy (neoadjuvant treatment) per clinical guidelines - You are between 18 and 75 years old - Your life expectancy is at least 6 months - You are able to comply with the study requirements **You may NOT be eligible if...** - You have severe heart, lung, bone marrow, liver, or kidney problems - You have intestinal perforation or complete bowel obstruction - You have uncontrolled diabetes - The investigator determines you are not suitable for participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06623487

Related Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT0416507046 locations

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT0685577170 locations

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

NCT071172141 location

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT0723069170 locations